Top in hem/onc: Updates in colorectal cancer
Click Here to Manage Email Alerts
A recent study presented at the Gastrointestinal Cancers Symposium revealed low health-related quality of life scores among young adult survivors of colorectal cancer. It was the top story in hematology/oncology last week.
Other top stories include data on colorectal cancer treatment from the symposium and the FDA’s decision to grant fast track designation to cavrotolimod (AST-008, Exicure) for skin cancer indications.
Read these and more in hematology/oncology below:
Young survivors of colorectal cancer report low health-related quality of life
Young adult survivors of colorectal cancer exhibited low overall health-related quality of life scores, with longer-term survivors reporting worse social and functional well-being than those diagnosed more recently. Read more.
One-third of colorectal cancer survival disparities a product of treatment gaps
Treatment disparities mediated about one-third of overall survival differences observed between white and Black patients with stage IV colorectal cancer, according to a retrospective cohort study presented at Gastrointestinal Cancers Symposium. Read more.
Triplet demonstrates activity in metastatic colorectal cancer
The combination of panitumumab (Vectibix, Amgen), ipilimumab (Yervoy, Bristol Myers Squibb) and nivolumab (Opdivo, Bristol Myers Squibb) induced responses among patients with metastatic colorectal cancer, phase 2 study results showed. Read more.
FDA grants fast track designation to AST-008 for skin cancer indications
The FDA granted fast track designation to cavrotolimod for two skin cancer indications, according to the agent’s manufacturer. Read more.
Atezolizumab-bevacizumab combination provides ‘longest survival seen’ in advanced HCC
Atezolizumab (Tecentriq, Genentech/Roche) plus bevacizumab (Avastin, Genentech) conferred the longest overall survival seen in a phase 3 study for treatment-naive advanced hepatocellular carcinoma, according to updated results of the IMbrave150 study presented at Gastrointestinal Cancers Symposium. Read more.